Discover 921 paid clinical trials in Hillsboro, Oregon. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 921
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
for
B-cell Acute Lymphoblastic Leukemia,
Location: Portland OR, Calgary, Salt Lake City UT, Los Angeles CA,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 0 - 25
Code: NCT06395103
Phase1, Phase2, Recruiting
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss
Location: Portland OR, Seattle WA, Los Angeles CA, La Jolla CA,
Sponsor: PMV Pharmaceuticals, Inc
Sex: All
Age: 12+
Code: NCT04585750
Phase1, Phase2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
for
Advanced Hepatocellular Carcinoma,
Location: Portland OR, Orange CA, Irvine CA, Pittsburgh PA
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06811116
Phase1, Phase2, Recruiting
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
for
Central Nervous System Nongerminomatous Germ Cell Tumor,
Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1
for
Relapsed/Refractory Acute Myeloid Leukemia
Location: Portland OR, Eugene OR, Seattle WA, Los Angeles CA,
Sponsor: SystImmune Inc.
Sex: All
Age: 18+
Code: NCT06714591
Phase1, Recruiting
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations